Friday | 21 November, 2008
Australian Biotechnology News

Stories about: Sigma

  • +

    Intelliheart tests in Amcal pharmacies 13/06/2008 12:08:09

    IM Medical to sell Intelliheart tests through Amcal pharmacies
  • +

    How the Bindeez were busted 25/01/2008 12:32:00

    Biochemical geneticist Kevin Carpenter discusses how he helped tracked down the blip in the Bindeez beads.
  • +

    Stocker rejoins CSIRO 02/07/2007 10:54:56

    Former CSIRO chief John Stocker is now chairman of the board.
  • +

    DNA-directed RNAi and the crown jewels 16/05/2007 10:55:31

    When Merck announced last year it was buying Sirna Therapeutics for over US$1 billion, the world sat up and took notice. RNAi was now being seen as not only a revolution in our understanding but something with an unimaginable dollar value as well.
  • +

    Reshaped Australian healthcare firms hold promise 06/02/2006 08:16:40

    Most of Australia's leading healthcare firms are expected to post strong first-half profit growth and provide positive outlook statements as the benefits of takeovers and spin-offs start to filter through, according to analysts.
  • +

    Benitec tells AGM of better times ahead 30/11/2005 14:27:48

    "Seeing you all here means the company has survived," the chairman of RNAi specialist Benitec (ASX:BLT) Ray Whitten, told shareholders at today's AGM in Sydney.
  • +

    CSIRO, Benitec strengthen RNAi patent positions 24/10/2005 15:04:24

    The legal mists are lifting from Black Mountain in Canberra, and Mountain View in California, clarifying the ownership of key patents on RNA interference (RNAi) gene silencing technology.
  • +

    Local pharma firms to distribute Funhaler 21/09/2005 12:32:15

    Perth-based biomedical devices developer Visiomed Group (ASX:VSG) has successfully competed negotiations with three pharmaceutical wholesale distributors in Australia for the distribution of its Funhaler incentive asthma spacer into Australian pharmacies.
  • +

    NeuroSolutions appoints Sigma Aldrich for scale-up 26/08/2005 14:47:19

    NeuroSolutions, the UK based subsidiary of newly listed neurology-focused biotech company NeuroDiscovery (ASX:NDL) has identified and selected Sigma Aldrich to provide scale-up and manufacturing services in relation to its lead pain drug candidate, NSL-043, which is due to enter a phase I clinical trial later this year.
  • +

    GroPep reports double profits 22/08/2005 14:27:59

    Adelaide-based GroPep (ASX:GRO) has recorded pre-tax profit of AUD$3.1 million for the year ending 30 June 2005, an increase of more than 200 per cent over the $1 million reported last year.
  • +

    Fluorotechnics secures deal with Sigma Aldrich 05/07/2005 14:48:29

    Macquarie University spinoff Fluorotechnics is establishing a reputation for lucrative liaisons with giants, announcing a global marketing agreement with Sigma Aldrich for its new-tech FluoroProfile protein-quantification kits.
Additional Resources
Newsletter Subscription
Sign up for our Australian Life Scientist newsletters!
 
Sponsored Links